Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chlormethine - Actelion Pharmaceuticals/Helsinn

Drug Profile

Chlormethine - Actelion Pharmaceuticals/Helsinn

Alternative Names: Clearazide™; Ledaga; LEDAGATM; Mechlorethamine gel; Nitrogen mustard topical gel; Topical nitrogen mustard; Valchlor

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yaupon Therapeutics
  • Developer Actelion Pharmaceuticals; Helsinn; Orphan Europe; Recordati Rare Diseases
  • Class Antineoplastics; Nitrogen mustard compounds; Small molecules
  • Mechanism of Action Alkylating agents; T-cell receptor gene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mycosis fungoides; Cutaneous T-cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Mycosis fungoides

Most Recent Events

  • 18 Oct 2022 Pharmacodynamics data from a preclinical in vitro study in Mycosis fungoides released by Helsinn
  • 21 Sep 2022 Launched for Mycosis fungoides (Second-line therapy or greater, In adults) in Canada (Topical) before September 2022
  • 01 Sep 2022 Juniper Biologics acquired distribution and supply license of Chlormethine from Helsinn in Australia, Afghanistan, Armenia, Azerbaijan, Bangladesh, Bhutan, Brunei, Cambodia, Georgia, India, Indonesia, Iraq, Kazakhstan, Kyrgyzstan, Laos, Malaysia, Mongolia, Myanmar, Nepal, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Tajikistan, Turkmenistan, Uzbekistan and Vietnam.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top